Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
University of Colorado, Denver
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05530356CT.gov Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study | — | Enrolling By Invitation | — | — | — |
NCT05008276CT.gov Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diabetic Kidney Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Iohexol (this asset) | University of Colorado, Denver | P1/2 | CCC · 52 |
| Folic Acid | Fuling Central Hospital of Chongqing City | P2/3 | BB |
| Valsartan | Columbia University | P4 | BB |
| Spironolactone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | BB |
| Simvastatin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Nifedipine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Lisinopril | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | BB |
| Finerenone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | B |
| Enalapril Maleate | Fuling Central Hospital of Chongqing City | P2/3 | B |
+9 more in the Diabetic Kidney Disease cohort
Other indications for Iohexol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P1/2 | CCC · 50 |
| Type 2 Diabetes Mellitus | — | P1/2 | CCC · 50 |
| Morbid Obesity | — | P1/2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Folic AcidFuling Central Hospital of Chongqing CityBB
- ValsartanColumbia UniversityBB
- SpironolactoneHospital de Messejana Dr. Carlos Alberto Studart GomesBB
- SimvastatinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)BB
- NifedipineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)BB
Citation
Floatz Terminal. Iohexol in Diabetic Kidney Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/iohexol-diabetic-kidney-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →